Skip to main content

$0.205 (0%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
2 July 2025 at 10:39am
Register to track RAP and receive email alerts.
Subject
RAP Ann: Suspension from Official Quotation

RAP Ann: Trading Halt

RAP Ann: Notification of cessation of securities - RAP

RAP Ann: Quarterly Activities Report and Appendix 4C

RAP Ann: Quarterly Results and Investor Conference Call Notification

RAP Ann: Proposed Acquisition of ResApp Health by Pfizer

RAP Ann: Investor Webinar

RAP Ann: Notification of cessation of securities - RAP

RAP Ann: Dartford and Gravesham NHS Trust to pilot ResAppDx

RAP Ann: COVID-19 Investor Presentation

RAP Ann: Reinstatement to Official Quotation

RAP Ann: ResApp announces positive results of COVID-19 screening test

RAP Ann: Suspension from Official Quotation

RAP Ann: Trading Halt

RAP Ann: Half Yearly Report and Accounts

RAP Ann: Health Teams to launch ResAppDx on aged care platform

RAP Ann: Cough analysis patent granted in China

RAP Ann: Quarterly Activities Report and Appendix 4C

RAP Ann: Quarterly Results and Investor Conference Call Notification

RAP Ann: Further appointments to COVID-19 Scientific Advisory Board

RAP Ann: ResAppDx goes live with Doctors on Demand in Australia

RAP Ann: LOI signed with Homify to launch ResAppDx in the Philippines

RAP Ann: Publication highlights use of ResAppDx in COVID-19 clinic

RAP Ann: Notification regarding unquoted securities - RAP

RAP Ann: US COVID-19 study completes recruitment

RAP Ann: ResAppDx goes live with Alodokter in Indonesia

RAP Ann: Distribution agreement with Sanrai International

RAP Ann: Change of Registry Address

RAP Ann: ResApp receives $818,826 in R&D tax incentive refund

RAP Ann: ResApp Establishes COVID-19 Scientific Advisory Board

RAP Ann: Results of Annual General Meeting

RAP Ann: Annual General Meeting Presentation

RAP Ann: Letter to Shareholders

RAP Ann: ResApp receives regulatory approvals for cough counter

RAP Ann: ResApp completes COVID-19 study recruitment in India

RAP Ann: Publication on challenges of diagnosing respiratory disease

RAP Ann: ResApp secures contract with global pharmaceutical company

RAP Ann: Partnership with Carepath for in-home COPD monitoring

RAP Ann: IRB approval for US COVID-19 study modification

RAP Ann: Jobkeeper Payments Notice

RAP Ann: Quarterly Activities Report and Appendix 4C

RAP Ann: Quarterly Results and Investor Conference Call Notification

RAP Ann: Notice of Annual General Meeting

RAP Ann: Presentations at Conferences

RAP Ann: COVID-19 Clinical Studies Update

RAP Ann: Notice under ASX Listing Rule 3.13.1

RAP Ann: ResApp announces FDA 510(k) submission for SleepCheckRx

RAP Ann: Notification regarding unquoted securities - RAP

RAP Ann: Notification of cessation of securities - RAP

RAP Ann: Change of Share Registry

Register to track RAP and receive email alerts.

Similar Companies

4DX
ALC
CGS
IME
M7T
MDR
PCK
PKS
PME